Allstate heads into its Q1 2026 earnings print on Thursday with call-side positioning at its most dominant reading in over a year — and the stock up 4.2% on the week to $224.58, already pricing in some optimism before a single number drops.
The options story has sharpened since Monday's earnings preview. The put/call ratio has fallen further to 1.02, now running nearly 2.4 standard deviations below its 20-day average of 1.21. That is the most call-heavy setup recorded in the past twelve months, eclipsing even the lows seen earlier this week. The shift is not subtle: a PCR of 1.02 against an average above 1.20 means options traders have materially reduced their put exposure heading into the report. The stock's 4.2% weekly gain reinforces that the move is not just a hedging rotation — there is genuine directional conviction in the options market right now.
Short interest tells a quieter story, and deliberately so. At 2.7% of the float, short positioning is low and barely moving — up just under 2% on the week from an already modest base. Borrowing costs have actually eased, falling 12% over the week to 0.38% annualised. Availability remains extraordinarily loose at nearly 2,900% — meaning there are roughly 29 shares available to borrow for every one currently shorted. There is no short-squeeze dynamic here. Bears who want to press into earnings face no meaningful friction in the lending market, but they are not pressing.
The Street is constructively positioned, though not unanimously so. Recent analyst actions have been a run of target raises: Keefe, Bruyette & Woods at $266, Piper Sandler at $268, and Wells Fargo at $243, all maintaining existing ratings rather than upgrading. The mean target of $241.50 implies roughly 7.5% upside from current levels — less than it did a week ago, given the price has moved. Citi sits at $226 with a Neutral, and Barclays holds an Underweight at $208, a target now below spot. The factor score picture supports the constructive lean: EPS momentum ranks in the 95th percentile on a 30-day basis and the 87th on 90-day, while the EPS surprise score sits at the 85th percentile. The ORTEX short score of 37.2 is mid-range and has been grinding lower all week — consistent with a market that is not building a short thesis here.
The institutional base is stable. Vanguard holds 12.9% and BlackRock 8.5%, both with marginal recent additions. Putnam added roughly 2.6 million shares as of end-March — the most material holder move in the top-fifteen. On the insider side, COO Mario Rizzo sold just over $4 million worth of stock on May 1, and CEO Tom Wilson executed a series of sales in March totalling roughly $5.7 million. The trades carry low significance scores and represent tiny fractions of outstanding shares, so they read as routine plan-driven activity rather than a directional signal.
Recent earnings reactions have been mild. The April 30 event produced a 2% next-day gain and faded to flat within five days. Prior prints generated moves under 0.5% on the day. The pattern is one of contained post-earnings volatility — which makes the current options enthusiasm slightly harder to reconcile with history. The key variables to watch on Thursday are the combined ratio trajectory against the 89.4% year-to-date reading, any update to personal auto policies-in-force growth, and whether management's commentary on loss cost normalisation matches the tone that drove analyst target upgrades earlier this month.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
